Lack of correlation between expression of Epstein-Barr virus (EBV) latent membrane protein and bcl-2 oncoprotein in vivo by Ho, FCS et al.
Title Lack of correlation between expression of Epstein-Barr virus(EBV) latent membrane protein and bcl-2 oncoprotein in vivo
Author(s) Tao, Q; Srivastava, G; Loke, SL; Ho, FCS
Citation Journal Of Clinical Pathology, 1994, v. 47 n. 7, p. 589-591
Issued Date 1994
URL http://hdl.handle.net/10722/43609
Rights Creative Commons: Attribution 3.0 Hong Kong License
J Clin Pathol 1994;47:589-591
Lack of correlation between expression of
Epstein-Barr virus (EBV) latent membrane
protein and bcl-2 oncoprotein in vivo
Q Tao, G Srivastava, S L Loke, F C S Ho
Abstract
Aims-To evaluate whether there is any
correlation between the expression of
Epstein-Barr virus (EBV) latent mem-
brane protein (LMP) and oncoprotein
bcl-2 in the lymph node biopsy specimens
of a Chinese patient with EBV-related
reactive lymphoproliferation who later
developed T cell lymphoma after a short
period oftime.
Methods-Immunohistochemistry, with
a standard alkaline phosphatase anti-
alkaline phosphatase (APAAP) method
and New Fuchsin as a chromogen, was
used for single staining of bcl-2 or LMP.
Double inmunostaining combining
APAAP and indirect immunofluores-
cence was performed for dual labelling of
LMP and bcl-2.
Results-bl-2 was expressed in 10-30%
of cells in the first lymph node biopsy
specimen (EBV-associated lymphoprolif-
erative disorder) and 30-50% of cells in
the second lymph node biopsy specimen
(T cell lymphoma). LMP was expressed
in the first biopsy specimen but not in the
second. Double inmunostaining results
showed that around 78% ofLMP positive
cells were bcl-2 negative and 94% bcl-2
positive cells were LMP negative. Among
the very small fraction of LMP and bcl-2
double positive cells, the intensity of bcl-2
staining was heterogeneous and was not
always stronger than that observed in
LMP negative bcl-2 positive cells.
Conclusions-The expression of bcl-2
protein is independent of LMI1P protein
status in vivo. Several mechanisms may
be involved in EBV associated
lymphomagenesis, and bcl-2 induction
may occur independently of LMP
expression.
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The bcl-2 proto-oncogene is located on the
long arm of chromosome 18 (18q21).' In fol-
licular lymphomas the expression of bcl-2
mRNA is deregulated through the 14;18
translocation with juxtaposition of bcl-2 gene
with the immunoglobulin heavy chain locus
on chromosome 14.' However, increased
expression of bcl-2 oncoprotein is not depen-
dent on the presence of a 14; 18 chromosomal
translocation.2 The bcl-2 protein is also
detectable in normal lymphoid tissues, and
expressed in a wide range of neoplastic and
lymphoproliferative diseases.3 Abnormally
high expression of bcl-2 has been associated
with resistance to apoptosis.4
Epstein-Barr virus (EBV) is associated with
several malignancies, including nasopharyn-
geal carcinomas,5 Burkitt's lymphomas,6
Hodgkin's disease,7 and lymphomas occurring
in immunocompromised8 or organ transplant
recipients.9 Gregory et al have shown that the
activation of EBV latent genes protects
human B cells from death by apoptosis.10
Recently, Finke et al reported that the expres-
sion of bcl-2 protein can be transactivated by
transfection ofEBV negative Burkitt's or non-
Hodgkin's lymphoma cell lines with EBV
latent membrane protein (LMP) gene carry-
ing expression vectors."I Moreover,
Henderson et al have also reported that the
induction of bcl-2 expression by LMP-1 pro-
tects B cells from apoptosis.12 Based on these
results, Finke et al have postulated that high
expression of bcl-2 induced by EBV is impor-
tant for the long term survival ofEBV positive
cells in seropositive subjects, and proposed
that rescue from apoptosis of lymphocytes by
EBV through induction of bcl-2 might be a
first important step in the tumorigenesis of
certain lymphomas in vitro. However, it
should be pointed out that all these studies
have been carried out using in vitro systems in
which LMP gene carrying retroviral vectors
were transfected to produce supraphysiologi-
cal concentrations of LMP proteins in EBV-
negative Burkitt's or non-Hodgkin's lym-
phoma cell lines. We therefore ask whether a
similar correlation also exists between the
expression ofLMP and bcl-2 in vivo. Here we
report our observation about the expression of
LMP and bcl-2 in a Chinese patient with EBV
related reactive lymphoproliferation who later
developed EBV negative T cell lymphoma
after a short period of time.
Case report
A 58 year old Chinese man presented initially
with generalised lymphadenopathy. A lymph
node biopsy specimen showed disturbed
architecture with a preponderance of large B
blasts mixed with numerous CD8 + T lym-
phocytes, consistent with an acute EBV infec-
tion. Immunohistochemical staining for K and
X light chains and gene rearrangement studies
confirmed the absence of clonal T or B cells.
Polyclonal episomal and linear EBV genome,
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consistent with lytic infection, was detected
by Southern blot analysis. The histological
features of the lymph node biopsy specimen
resembled those of a reactive lymphoprolifera-
tive lesion. After biopsy lymph node enlarge-
ment spontaneously regressed, but
lymphadenopathy recurred eight months
later, and the second lymph node biopsy spec-
imen showed T cell lymphoma, confirmed by
detection of clonally rearranged T cell recep-
tor J chain gene on Southern blot analysis.
However, EBV genome could not be detected
in the second biopsy specimen by Southern
blot hybridisation and also by in situ hybridis-
ation using fluorescein isothiocyanate (FITC)
conjugated oligomer probe for EBV encoded
EBER RNA (Dako Japan Co. Ltd). The
patient died of hepatic encephalopathy five
months after chemotherapy. A necropsy was
not performed.
A
B
Figure 1 Immunostaining for bcl-2 protein using alkaline phosphatase anti-alkaline
phosphatase (APAAP) on cryostat sections. (A) first biopsy specimen (EBVrelated
reactive lymphoproliferation); (B) second biopsy specimen (EBVnegative T cell
lymphoma).
Methods
For immunohistochemistry, a standard alka-
line phosphatase anti-alkaline phosphatase
(APAAP) method was used on cryostat sec-
tions. New Fuchsin was used as substrate.
Normal rabbit serum or anti-chromogranin
were used as negative controls. Cytospin
slides of EBV infected Raji cell line (latent),
p3HRI, and B95-8 (lytic) were used as posi-
tive controls for bcl-2 or LMP. Double
immunostaining was performed essentially as
described by Ramshaw and Parums"3 by com-
bining APAAP and indirect immunofluores-
cence, but using New Fuchsin as substrate
instead of Fast Red for APAAP.
Results
Strong expression of LMP (using CS. 1-4
monoclonal antibody, courtesy of Dr M
Rowe) was detected in about 15% of cells in
the first lymph node biopsy specimen (EBV
related reactive lymphoproliferation) by
immunostaining. bcl-2 protein was also
detectable in 10-30% of total cells (using
antigen to bcl-2 antibody, courtesy of Dr D
Mason) (fig lA). Using a double immuno-
staining method, we were able to study the
association between the expression of these
two proteins. Results showed that there was
no correlation between the expression of
LMP and bcl-2. Around 78% ofLMP positive
cells were bcl-2 negative and 94% bcl-2 posi-
tive cells were LMP negative (fig 2). Even
among the very low percentage of both LMP
and bcl-2 positive cells, the staining intensity
of bcl-2 also varied from weak to strong and
these LMP and bcl-2 positive cells did not
always have stronger staining than that of
LMP negative bcl-2 positive cells. This pat-
tern is similar to the staining of bcl-2 and
LMP in a Raji cell line. bcl-2 protein was still
detectable in 30-50% of cells in the second
tumour biopsy specimen in which EBV could
not be detected, and there were no differences
in the staining intensities of bcl-2 between the
first biopsy specimen and the second lym-
phoma biopsy specimen (fig 1 B).
Discussion
bcl-2 is expressed in a series of normal and
neoplastic lymphoid tissues. High non-physi-
ological concentrations of LMP may induce
the expression of bcl-2 in vitro. However, the
expression ofLMP was rarely followed by bcl-
2 expression in vivo in our case. Moreover,
lack of correlation between the expression of
LMP and bcl-2 in Hodgkin's disease'415 and
nasopharyngeal carcinomas'6 has been
described recently. Martin et al have also
recently reported the lack of correlation
between LMP and bcl-2 in human B cells
which were transfected in vitro with LMP
expression vectors.'7 Furthermore, no signifi-
cant correlation between the expression of
LMP and the activation markers CD23 or
CD25 was observed in the first biopsy speci-
men of the patient described in this report (Q
Tao, unpublished results), which agrees with
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Figure 2 Double immunostaining combining APAAPfor bcl-2 protein and indirect
immunofluorescence (FITC) for LMP on the cryostat section of the first biopsy specimen
(EBV-related reactive lymphoproliferation). Double exposure of the transmitted brightfield
illumination and FITC immunofluorescence is shown. Arrow: LMP negative and bcl-2
positive cells; arrowhead: LMPpositive and bcl-2 negative cells.
the recent reports by other groups.'418 The
life-long persistence of EBV in seropositive
subjects is unlikely to depend on the long
term survival of EBV positive cells with high
expression of bcl-2 induced by LMP.
Conversely, cells which express LMP at high
concentrations will provide antigenic sites
recognisable by cytotoxic T cells and would
be removed rapidly. Other mechanisms for
life-long persistence may be more important,
including latent infection by EBV in epithe-
lium and lymphocytes with periodic activation
of a lytic infection cycle, leading to a reservoir
of latently infected cells.
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